ONO PHARMACEUTICAL CO
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 144
- Registration Number
- NCT06948448
ONO-4538 Study in Patients With Richter's Transformation
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 14
- Registration Number
- NCT06936943
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
🇯🇵Hokkaido University Hospital, Sapporo, Hokkaido, Japan
🇯🇵Kyusyu University Hospital, Fukuoka, Japan
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 240
- Registration Number
- NCT06881836
- Locations
- 🇺🇸
Profound Research LLC at The Neurology Center of Southern California, Carlsbad, California, United States
🇺🇸Ark Clinical Research, Fountain Valley, California, United States
🇺🇸Sunwise Clinical Research, Walnut Creek, California, United States
A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06816108
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
🇯🇵Osaka International Cancer Institute, Osaka-shi, Osaka, Japan
🇯🇵The Cancer Institute Hospital Of JFCR, Koto-Ku, Tokyo, Japan
A Study of ONO-1110 in Patients With Social Anxiety Disorder
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT06805565
- Locations
- 🇯🇵
Kokura Mental Clinic, Fukuoka, Japan
A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
- Conditions
- Agitation Associated With Alzheimer's Disease Dementia
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-01-31
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT06803823
- Locations
- 🇯🇵
Hotei Hospital, Aichi, Japan
🇯🇵Akita Prefectural Center For Rehabilitation and Psychiatric Medicine, Akita, Japan
🇯🇵Medical Corporation Keishinkai Kyowa Hospital, Akita, Japan
A Study of ONO-1110 in Patients With Major Depressive Disorder
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT06792136
- Locations
- 🇯🇵
Kokura Mental Clinic, Fukuoka, Japan
A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial Cystitis
- Conditions
- Hunner Type Interstitial Cystitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 50
- Registration Number
- NCT06752603
- Locations
- 🇯🇵
Nagoya University Hospital, Nagoya, Aichi, Japan
🇯🇵Shinshu University Hospital, Matsumoto, Nagano, Japan
🇯🇵The Jikei University Hospital, Minato-Ku, Tokyo, Japan
A Clinical Study of ONO-1110 in Patients With Fibromyalgia
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 160
- Registration Number
- NCT06752590
- Locations
- 🇯🇵
Women's Clinic Luna, Yokohama, Kanagawa, Japan
🇯🇵Ikebukuro Internal Medicine, Tokyo, Japan
🇯🇵Juntendo University Hospital, Tokyo, Japan
Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: a Nationwide Study
- Conditions
- Primary Central Nervous System Lymphoma (PCNSL)
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 35
- Registration Number
- NCT06714370